Clinical Trials Browser

Phase 2 × Completed × Breast × Clear all

NCT04296162 2026-05-26

ORCHID

Phase 2 Completed

Breast Neoplasms

NCT03627988 2026-05-22

MARTA

Phase 2 Completed

Breast Cancer Invasive

NCT04489173 2026-05-22

TIBET

Phase 2 Completed

Breast Neoplasms

NCT04699630 2026-05-22

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Phase 2 Completed

121 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06188559 2026-05-22

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Phase 2 Completed

230 enrolled 24 charts

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT03624478 2026-05-15

Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery

Phase 2 Completed

25 enrolled 11 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT00631852 2026-05-12

A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer

Phase 2 Completed

16 enrolled 28 charts

Breast Neoplasms

NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04268134 2026-05-06

ALTA

Phase 2 Completed

77 enrolled 13 charts

Breast Neoplasms

NCT01670500 2026-05-05

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

Phase 2 Completed

118 enrolled 23 charts

Breast Neoplasms

NCT03797326 2026-05-04

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05865990 2026-05-04

TUXEDO-3

Phase 2 Completed

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms

NCT02700386 2026-04-30

Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes

Phase 2 Completed

108 enrolled 14 charts

Breast Neoplasms, Neoplasms

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Completed

93 enrolled 16 charts

Estrogen Receptor-positive Breast Cancer

NCT02576431 2026-04-28

NAVIGATE

Phase 2 Completed

215 enrolled 2 FDA

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT03483012 2026-04-21

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Phase 2 Completed

6 enrolled 19 charts

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT02928978 2026-04-13

TBCRC042

Phase 2 Completed

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT07162051 2026-04-13

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2 Completed

344 enrolled 11 charts

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04796623 2026-04-08

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Phase 2 Completed

HR-positive, HER2-negative Advanced Breast Cancer

NCT07307911 2026-04-08

Co-Pa-N

Phase 2 Completed

Breast Neoplasms

NCT05394285 2026-04-06

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03947151 2026-03-31

DEGASTIM

Phase 2 Completed

Carcinoma, Ductal, Breast

NCT05376241 2026-03-27

Promoting Informed Choice for Breast Cancer Screening

Phase 2 Completed

637 enrolled 10 charts

Breast Neoplasms

NCT02654119 2026-03-23

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Phase 2 Completed

20 enrolled 12 charts

Breast Neoplasms

NCT04539938 2026-03-23

HER2CLIMB-04

Phase 2 Completed

70 enrolled 23 charts

Breast Neoplasms

NCT05659563 2026-03-19

EMPRESS

Phase 2 Completed

92 enrolled 14 charts

Breast Neoplasms

NCT00417495 2026-03-16

IGASSU

Phase 2 Completed

Adenocarcinoma, Breast Neoplasms

NCT01658462 2026-03-16

VAROCE

Phase 2 Completed

Breast Neoplasms

NCT03747042 2026-03-16

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Phase 2 Completed

61 enrolled 5 charts

Breast Cancer Female

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Phase 2 Completed

50 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02860000 2026-02-27

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Phase 2 Completed

96 enrolled 34 charts

Breast Neoplasms

NCT05896566 2026-02-24

PREcoopERA

Phase 2 Completed

Breast Neoplasms

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Phase 2 Completed

41 enrolled 9 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01853748 2026-02-19

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Phase 2 Completed

512 enrolled 28 charts

Breast Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Phase 2 Completed

19 enrolled 10 charts

Breast Neoplasms

NCT06975085 2026-02-12

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study

Phase 2 Completed

Breast Cancer Female

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Phase 2 Completed

23 enrolled 10 charts

Breast Neoplasms

NCT04758780 2026-02-05

OPALESCENCE

Phase 2 Completed

12 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04275661 2026-02-04

Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery

Phase 2 Completed

Agnosia, Breast Neoplasms

NCT03781063 2026-01-28

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Phase 2 Completed

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms